Please assess the completion status of the following clinical trial:

Trial Title: Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 18 to 60 years on the day of inclusion.~* Informed consent form signed.~* Able to attend all scheduled visits and to comply with all trial procedures.~* For a woman, inability to bear a child or negative urine pregnancy test at the first visit.~Exclusion Criteria :~* Systemic hypersensitivity to egg proteins, chick proteins, or any of the vaccine components, in particular, neomycin, formaldehyde, and octoxinol 9, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances.~* Febrile illness (oral temperature \>= 37.5°C, or rectal equivalent temperature \>= 38.0°C) on the day of inclusion.~* Participation in another clinical trial in the 4 weeks preceding the trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.~* Unstable chronic illness (defined as illness requiring hospitalization or a clinically significant change in medication in the 12 weeks prior to inclusion) at a stage that could interfere with trial conduct or completion.~* Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures.~* Blood or blood-derived products received in the past 3 months.~* Any vaccination in the 4 weeks preceding the trial vaccination.~* Vaccination planned in the 4 weeks following the trial vaccination.~* Previous vaccination against influenza (in the previous 6 months).~* Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.~* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Lot 1
- 2 (Type: EXPERIMENTAL): Lot 2
- 3 (Type: EXPERIMENTAL): Lot 3
- 4 (Type: ACTIVE_COMPARATOR): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).